# THE TRANSGLYCOSYLATION OF KANAMYCIN A

Sir:

In our previous paper in this series<sup>1)</sup> we reported the transglycosylation of neamine (to form 5-glucosylneamine) which resulted in increased antibiotic potency *in vitro*. We have extended PAN's system<sup>2)</sup> to other antibiotics and wish to report our observations on glycosylated kanamycin A.

This material was prepared by adding 1 g kanamycin A<sup>3</sup>), 4 g maltose, and 1 g Clarase<sup>R</sup> to 40 ml of McILVAINE'S pH 4.0 buffer and incubating the solution for 96 hours at 50°C. After this period new ninhydrin-positive and biologically active components were observed upon paper ionophoresis of the mixture (pH 1.8, 53 volts/cm, 20 minutes) and in silica gel thin-layer chromatography (using CHCl<sub>3</sub> – MeOH – NH<sub>4</sub>OH, 1:3:2).

The reaction mixture was diluted 3-fold with water and the pH adjusted to 8 with NaOH. The diluted solution was then passed through CG 50 resin (NH<sub>4</sub><sup>+</sup> cycle, 30 ml column). The biologically active components (against *Staphylococcus aureus*) were eluted with NH<sub>4</sub>OH gradient of  $0\sim0.5$  N NH<sub>4</sub>OH. The crude material was purified by rechromatographing on CG 50 (NH<sub>4</sub><sup>+</sup> cycle, 50 ml column) using 0.1 N NH<sub>4</sub>OH as eluting solution, and the active fractions were lyophilized.

Analysis of the purified material gave C, 40.20 %, N 7.85 %. The C/N ratio of 5.9 is close to the C/N ratio of 6.0 expected for a glycosylated kanamycin A. The biological activity of this material was considerably less than the kanamycin A, having about 50 % of the activity against *Bacillus*  subtilis Marburg, and less than 1% against S. aureus FDA 209P, Sarcina lutea, Escherichia coli, and Pseudomonas aeruginosa. In vivo studies showed the kanamycin A derivative had about 25% of the activity of the parent compound in mice infected with S. aureus, and less than 1% of the activity of the parent compound in mice infected with E. coli.

#### Acknowledgements

The authors are indebted to Dr. M. STERNBERG, Miles Laboratories for the Clarase<sup>R</sup>, and to Dr. K. E. PRICE, Bristol Laboratories for the kanamycin. This program was supported by a grant from the U. S. Public Health Servic (NIH AI-09320).

### T. Endō\*

## D. Perlman

School of Pharmacy University of Wisconsin, Madison, Wisconsin, USA

\* Present address: Institute of Applied Microbiology, The University of Tokyo, Tokyo, Japan

(Received October 26, 1972)

#### References

- ENDŌ, T. & D. PERLMAN: Transglycosylation of neamine. J. Antibiotics 25:681~ 682, 1972
- PAN, S.C.; L.W. NICHOLSON & P. KOLOCHOV: Enzymic synthesis of oligosaccharides. Arch. Biochem. Biophys. 42: 406~420, 1953
- 3) UMEZAWA, H.; M. UEDA, K. MAEDA, K. YAGISHITA, S. KONDO, Y. OKAMI, R. UTAHARA, T. OSATO, K. NITTA & T. TAKEUCHI: Production and isolation of a new antibiotic, kanamycin. J. Antibiotics, Ser. A 10:181~ 188, 1957